(5-苯基-1-对甲苯基-1H-吡唑-3-基)-甲醇 | 1027409-93-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (5-苯基-1-对甲苯基-1H-吡唑-3-基)-甲醇
• 英文名称: [1-(4-Methylphenyl)-5-phenylpyrazol-3-yl]methanol
• CAS: 1027409-93-3
• 化学式: C₁₇H₁₆N₂O
• 分子量: 264.327
• InChiKey: SOIWIJFTBYPZPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5-苯基-1-对甲苯基-1H-吡唑-3-基)-甲醇 在 三苯基膦 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 反应 15.5h， 以360 mg的产率得到3-bromomethyl-1-(4-methylphenyl)-5-phenyl-1H-pyrazole
  参考文献：
  名称：

  New COX-2/5-LOX Inhibitors:  Apoptosis-Inducing Agents Potentially Useful in Prostate Cancer Chemotherapy

  摘要：

  The arachidonic acid metabolizing enzymes cyclooxygenase-2 (COX-2) and lipoxygenases (LOXs) have been found to be implicated in a variety of cancers, including prostate cancer. To develop new therapeutic treatments, it therefore seemed interesting to design dual COX-2/5-LOX inhibitors. We report here the synthesis and in vitro pharmacological properties of diarylpyrazole derivatives that have in their structure key pharmacophoric elements to obtain optimal interaction with subsites of active pockets in both enzyme systems. Using a molecular modeling approach, a set of SAR data is proposed, highlighting the importance of the sulfonyl group of one of the aryl moieties in terms of proliferation inhibition and/or apoptosis induction.

  DOI：

  10.1021/jm0407761
• 作为产物：
  描述：

  ethyl 4-hydroxy-2-oxo-4-phenylbut-3-enoate 在 锂硼氢 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 75.0h， 生成 (5-苯基-1-对甲苯基-1H-吡唑-3-基)-甲醇
  参考文献：
  名称：

  New COX-2/5-LOX Inhibitors:  Apoptosis-Inducing Agents Potentially Useful in Prostate Cancer Chemotherapy

  摘要：

  The arachidonic acid metabolizing enzymes cyclooxygenase-2 (COX-2) and lipoxygenases (LOXs) have been found to be implicated in a variety of cancers, including prostate cancer. To develop new therapeutic treatments, it therefore seemed interesting to design dual COX-2/5-LOX inhibitors. We report here the synthesis and in vitro pharmacological properties of diarylpyrazole derivatives that have in their structure key pharmacophoric elements to obtain optimal interaction with subsites of active pockets in both enzyme systems. Using a molecular modeling approach, a set of SAR data is proposed, highlighting the importance of the sulfonyl group of one of the aryl moieties in terms of proliferation inhibition and/or apoptosis induction.

  DOI：

  10.1021/jm0407761

文献信息

• CYCLOHEXANE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：Toray Industries, Inc.

  公开号：EP2341047A1

  公开（公告）日：2011-07-06

  The present invention aims to provide a compound having a strong analgesic action against both nociceptive pain and neuropathic pain and having less side effects, and a medical use thereof. The present invention provides cyclohexane derivatives represented by the following compound, or pharmaceutically acceptable salts thereof or prodrugs thereof.

  本发明旨在提供一种对痛觉痛和神经病理性痛均有较强镇痛作用且副作用较小的化合物及其医疗用途。本发明提供以下列化合物为代表的环己烷衍生物，或其药学上可接受的盐或其原药。
• [EN] THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR FIBROMYALGIA<br/>[FR] AGENT THÉRAPEUTIQUE OU AGENT PROPHYLACTIQUE POUR LA FIBROMYALGIE
  申请人：TORAY INDUSTRIES

  公开号：WO2011125836A1

  公开（公告）日：2011-10-13

  　本発明は、侵害受容性疼痛及び神経因性疼痛の双方に対して鎮痛効果を有し、線維筋痛症の治療に対して有効な治療剤又は予防剤を提供することを目的としている。本発明は、下式に代表されるシクロヘキサン誘導体又はその薬理学的に許容される塩若しくはそのプロドラッグを有効成分として含有する、線維筋痛症の治療剤又は予防剤を提供する。
• [EN] THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR URINE COLLECTION DISORDER<br/>[FR] AGENT THÉRAPEUTIQUE OU AGENT PRÉVENTIF POUR LES TROUBLES DE COLLECTE DE L'URINE
  申请人：TORAY INDUSTRIES

  公开号：WO2011125838A1

  公开（公告）日：2011-10-13

  　本発明は、抗コリン作用に基づく副作用が改善され、かつ、鎮痛作用を併せ持つ、蓄尿障害の治療に対して有効な治療剤又は予防剤を提供することを目的としている。本発明は、下式に代表されるシクロヘキサン誘導体、その薬理学的に許容される塩又はそのプロドラッグを有効成分として含有する、蓄尿障害の治療剤又は予防剤を提供する。
• New COX-2/5-LOX Inhibitors:  Apoptosis-Inducing Agents Potentially Useful in Prostate Cancer Chemotherapy
  作者：Nicole Pommery、Thierry Taverne、Aurélie Telliez、Laurence Goossens、Caroline Charlier、Jean Pommery、Jean-François Goossens、Raymond Houssin、François Durant、Jean-Pierre Hénichart

  DOI：10.1021/jm0407761

  日期：2004.12.1

  The arachidonic acid metabolizing enzymes cyclooxygenase-2 (COX-2) and lipoxygenases (LOXs) have been found to be implicated in a variety of cancers, including prostate cancer. To develop new therapeutic treatments, it therefore seemed interesting to design dual COX-2/5-LOX inhibitors. We report here the synthesis and in vitro pharmacological properties of diarylpyrazole derivatives that have in their structure key pharmacophoric elements to obtain optimal interaction with subsites of active pockets in both enzyme systems. Using a molecular modeling approach, a set of SAR data is proposed, highlighting the importance of the sulfonyl group of one of the aryl moieties in terms of proliferation inhibition and/or apoptosis induction.